Clinical Trials

CTS-1027 has recently entered a Phase 2 clinical trial as a therapy for liver damage associated with infection by hepatitis C virus. CTS-1027 is designed to address disease in HCV treatment failures (approximately 1 million patients in the US today) with a unique approach that minimizes inflammation, abnormal cell death and fibrogenesis associated with this chronic viral infection. The goals for this Phase 2 clinical trial with CTS-1027 are to establish safety and activity in chronic HCV infected patients who have failed existing, approved treatments. Patients treated with CTS-1027 could theoretically maintain normal liver function indefinitely even in the presence of persistent viral infection. This drug may also be evaluated for use as adjunct treatment in combination with HCV antiviral therapy. Initial results from the current trial are expected to be available in the second half of 2008.

For more detailed information about the current clinical trial, please visit clinicaltrials.gov at the specific web address below:

http://clinicaltrials.gov/ct2/show/NCT00570336?term=CTS-1027&rank=1